-

Agilent Announces the Innovative Mito-rOCR Assay Kit for Mitochondrial Research

Streamlined solution for mitochondrial assessment democratizes cell analysis making it accessible to more researchers

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announces the new Mito-rOCR Assay Kit. This easy and streamlined end-to-end solution makes sophisticated analysis of mitochondrial function available to researchers of all skill levels. With this cost-effective and versatile kit, researchers can easily incorporate functional assessment of relative mitochondrial respiration into their cell physiology and disease pathology studies.

Mitochondria are central to energy production processes that drive cellular activity, and mitochondrial dysfunction is linked to numerous diseases and conditions. The Mito-rOCR assay enables more researchers to explore this crucial aspect of biology with accuracy and ease. The assay can be used with various compatible fluorescent plate readers and multimode imagers that meet its requirements for sensitivity, detection capabilities, and environmental control.

For example, the BioTek Cytation series of fluorescence plate readers and multimode imagers are ideal for the Mito-rOCR assay. Their advanced software allows them to handle various applications, maintain optimal conditions, and automate processes, making them reliable and adaptable for different research needs.

The Mito-rOCR assay measures cells’ relative oxygen consumption rate (rOCR), enabling sensitive detection of changes in mitochondrial function. This approach offers thorough insights into mitochondrial health and performance. With the Mito-rOCR Assay Kit, compounds are reconstituted directly in the assay medium, eliminating the need for additional solvents.

Notably, the assay is also reversible; the reagent remains outside the cells to prevent interference with cellular processes and can be easily removed to allow further downstream analyses. Data analysis is conducted using the Mito-rOCR Analysis Module within Agilent Seahorse Analytics. This cloud-based software makes importing data, linearizing signals, calculating slopes, and generating data tables and bar charts easy and streamlined.

Chris Braun, associate vice president of Marketing in Agilent’s Cell Analysis Division, commented on the importance of this announcement. “The Agilent Mito-rOCR Assay Kit was developed in direct response to customer feedback, as they told us they needed an easy-to-use assay that works with various fluorescence plate readers. The Mito-rOCR Assay Kit delivers this with a robust assay that supports multiplexing. This innovative assay democratizes the measurement of relative oxygen consumption rate in live cells, enabling more researchers to study cellular respiration and related biological processes.”

A key part of Agilent’s family of metabolic analysis solutions, the Mito-rOCR Assay Kit further expands Agilent’s broad range of uniquely enabling tools for interrogating cellular metabolism. These tools deliver a functional view of cell metabolism to more scientists, facilitating scientific advancement and accelerating discovery across critical areas of biological investigation.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. Second-quarter GAAP net income was $339 million, or $1.20 per share. This compares with $215 million, or $0.75 per share, in the second quarter of 2025. Non-GAAP net income(3) was $423 million, or $1.49 per share, during the quarter, compar...

Agilent Launches New GC Systems with GC Assist to Improve Laboratory Efficiency and Data Quality

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the new 8890B GC and 8860B GC with GC Assist. GC Assist is the new, advanced instrument intelligence that provides system monitoring, built-in troubleshooting, and remote connectivity to analytical instrumentation within the laboratory’s secure network. These systems enable higher performance and productivity across gas chromatography analyses. The new systems are designed to help laboratorie...

Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutical quality control (QC) laboratories implement liquid chromatography high-resolution mass spectrometry (LC/HRMS) in routine, regulated testing environments. The Agilent MAM solution brings together software, instrumentation, columns, consumables and standards to address practical and operational ba...
Back to Newsroom